Bio-Path Holdings, Inc. operates as a biotechnology company which focuses on the development of targeted therapies for acute myeloid leukemia, chronic myeloid leukemia, and other types of cancer. Its drug candidates include prexigebersen and Liposomal Bcl2. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein, and Ana Maria Tari on May 10, 2007 and is headquartered in Bellaire, TX.
